Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 3/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 5/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | USP1 | O94782 | 1/20 | 0.31 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14930355 | 0.82 | CHRNB2 (0.41) | PRMT5MAP3K12PIK3CALRRK2USP1 | |
| SCHEMBL14925514 | 0.79 | USP1 (0.35) | PRMT5MAP3K12MTORPIK3CAUSP1 | |
| SCHEMBL19965717 | 0.78 | PIK3CA (0.43) | MAP3K12PARP1MTORPIK3CA | |
| SCHEMBL19441976 | 0.77 | MAP3K12 (0.38) | MAP3K12MTORPIK3CA | |
| SCHEMBL18291649 | 0.76 | OPRM1 (0.41) | PARP1 | |
| SCHEMBL19441974 | 0.76 | BTK (0.38) | BTK | |
| SCHEMBL23103391 | 0.75 | AR (0.41) | PRMT5MAP3K12PARP1 | |
| SCHEMBL23114428 | 0.75 | AR (0.41) | PRMT5MAP3K12PARP1 | |
| SCHEMBL23107398 | 0.75 | AR (0.41) | PRMT5MAP3K12PARP1 | |
| SCHEMBL21769123 | 0.75 | BTK (0.38) | MAP3K12PARP1MTORPIK3CABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079002-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-20180071286-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | GENENTECH, INC. (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071286-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | TYK2, BTK, PDXK | PRMT5 2305/4885MAP3K12 114/4885PARP1 734/4885 |
| US-20210079002-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | PRMT5 2131/4885MAP3K12 109/4885PARP1 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.